Disclosures: The study was funded in part by a consortium of Disphar, Teva and Tiofarma. Opstal reports no relevant financial disclosures. Please see the study for the other authors’ relevant financial disclosures. Tardif reports receiving grant support from Amarin, AstraZeneca, Ceapro, DalCor Pharmaceuticals, Esperion, Ionis, Novartis, Pfizer, RegenXBio and Sanofi; receiving honoraria from AstraZeneca, DalCor Pharmaceuticals, HLS Pharmaceuticals, Pendopharm and Sanofi; having minor equity interest in DalCor Pharmaceuticals; and is mentioned as an author on submitted patents on pharmacogenomics-guided CETP inhibition, use of colchicine after MI, and use of colchicine in COVID-19 (he has waived his rights in the colchicine patents and does not stand to gain financially). Marquis-Gravel reports receiving research grants from Bayer; receiving speaker honoraria from Novartis; and serving on national advisory boards for Bayer, JAMP and Servier.
August 26, 2021
2 min read
Save

LoDoCo2: Colchicine benefits consistent regardless of ACS history, timing

Disclosures: The study was funded in part by a consortium of Disphar, Teva and Tiofarma. Opstal reports no relevant financial disclosures. Please see the study for the other authors’ relevant financial disclosures. Tardif reports receiving grant support from Amarin, AstraZeneca, Ceapro, DalCor Pharmaceuticals, Esperion, Ionis, Novartis, Pfizer, RegenXBio and Sanofi; receiving honoraria from AstraZeneca, DalCor Pharmaceuticals, HLS Pharmaceuticals, Pendopharm and Sanofi; having minor equity interest in DalCor Pharmaceuticals; and is mentioned as an author on submitted patents on pharmacogenomics-guided CETP inhibition, use of colchicine after MI, and use of colchicine in COVID-19 (he has waived his rights in the colchicine patents and does not stand to gain financially). Marquis-Gravel reports receiving research grants from Bayer; receiving speaker honoraria from Novartis; and serving on national advisory boards for Bayer, JAMP and Servier.
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

In patients with chronic coronary disease, the beneficial effects of colchicine were consistent regardless of history of ACS and time of treatment following ACS, according to new data from the LoDoCo2 trial.

As Healio previously reported, in the main results of LoDoCo2, in patients with chronic coronary syndrome on optimal medical therapy, colchicine 0.5 mg per day reduced CV events by 31% compared with placebo. For the present analysis of 5,522 patients, Tjerk S.J. Opstal, MD, cardiologist at Radboud University Medical Center, Nijmegen, the Netherlands, and colleagues assessed whether the treatment effect of colchicine in LoDoCo2 varied by ACS history.

heart beat drawing
Source: Adobe Stock

Participants were stratified into four groups: those with no prior ACS; those with recent ACS, defined as 6 to 24 months; those with remote ACS, defined as 2 to 7 years; and those with very remote ACS, defined as more than 7 years.

According to the researchers, the primary endpoint of CV death, spontaneous MI, ischemic stroke or ischemia-driven coronary revascularization favored colchicine over placebo in all four groups (P for interaction = .59):

  • No prior ACS: 2.8 events per 100 person-years vs. 3.4 events per 100 person-years; HR = 0.81; 95% CI, 0.52-1.27;
  • Recent ACS: 2.4 events per 100 person-years vs. 3.3 events per 100 person-years; HR = 0.75; 95% CI, 0.51-1.1;
  • Remote ACS: 1.8 events per 100 person-years vs. 3.2 events per 100 person-years; HR = 0.55; 95% CI, 0.37-0.82; and
  • Very remote ACS: 3 events per 100 person-years vs. 4.3 events per 100 person-years; HR = 0.7; 95% CI, 0.51-0.96.
Jean-Claude Tardif

In a related editorial, Jean-Claude Tardif, MD, director of the Montreal Heart Institute Research Center and professor of medicine at the Université de Montréal, and Guillaume Marquis-Gravel, MD, MSc, assistant professor of medicine at the Université de Montréal, wrote that “These data support the evolving story showing benefits of colchicine therapy in patients with coronary artery disease, including those presenting with acute coronary syndromes.

“In light of the positive results from LoDoCo2, COLCOT, and meta-analyses; its good tolerability profile; and cost-effectiveness, inflammation reduction with low-dose colchicine should be considered to treat patients with coronary disease in the absence of severe renal dysfunction,” Tardif and Marquis-Gravel wrote.

Reference: